Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

EXPLAINED: 8 | Vintage Vibes

Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose

Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a

Benzinga

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Benzinga

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's Why Moderna Shares Are Rising

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 7.0% at $158.42. The company announced today it has reached an agreement with Japan to supply an additional 70 million doses of its COVID-19 booster vaccine.

Benzinga

Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble…

Benzinga

GeoVax Labs Retains CATO SMS To Manage Its Mid-Stage COVID-19 Vaccine Trials

GeoVax Labs Inc (NASDAQ:GOVX) has engaged CATO SMS to manage its two ongoing Phase 2 trials of its COVID-19 vaccine candidate, GEO-CM04S1. One is testing the safety and effectiveness of GEO-CM04S1 compared to the Pfizer Inc (NASDAQ:PFE) / BioNTech SE (NASDAQ:BNTX) in immunosuppressed patients with blood cancer. The other trial is testing GEO-CM04S1 as a booster in…

Benzinga

What Are Whales Doing With Moderna

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 59 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Here's Why Moderna Shares Are Rising On Monday

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 18.9% at $164.27 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine.

Benzinga

Moderna Starts Dosing In Mid-Stage Omicron-Specific Bivalent Booster Candidate

Moderna Inc (NASDAQ: MRNA) has

Benzinga

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 40 strange trades.

Benzinga

Moderna Plans Vaccines Against 15 Pathogens With Future Pandemic Potential

Moderna Inc (NASDAQ: MRNA) plans to develop and begin testing vaccines targeting 15 pathogens identified as the biggest public health risk by WHO and CEPI by 2025. The Company also said it would permanently wave its COVID-19 vaccine patents for shots intended for certain low- and middle-income countries. At its global public health strategy,…

Benzinga

The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Moderna To Set Up mRNA Vaccine Manufacturing Facility In Kenya

Moderna Inc (NASDAQ:MRNA) would set up a manufacturing facility in Kenya, its first in Africa, to produce messenger RNA (mRNA) vaccines, including COVID-19 shots. Moderna expects to invest about $500 million in the Kenyan facility and supply as many as 500 million doses of mRNA vaccines to the continent each year. It also…

Benzinga

Moderna Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 43 strange trades.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Moderna Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 18 strange trades.

Benzinga

Technical Levels For Salesforce Investors To Watch After Earnings

Saleforce.com Inc. (NASDAQ: MRNA) shares are trading higher Wednesday after the company reported better-than-expected fourth-quarter financial results and issued guidance above estimates.

Benzinga

Expert Ratings For Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

StockNews.com

3 Worst Performing Stocks in the S&P 500 Year-to-Date

S&P 500 stocks have been plummeting amid concerns about tighter monetary policy and the escalating war between Russia and Ukraine. This has triggered further selloffs, causing renowned stocks PayPal (PYPL), Moderna (MRNA), and EPAM Systems (EPAM) to lose momentum lately. Let’s discuss.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for

Benzinga

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Longer Waiting Period Between mRNA COVID-19 Doses May Cut Heart Inflammation Risk, CDC Suggests

The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc's (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna

Benzinga

Will Moderna Be 'One Of The Most Valuable Healthcare Companies' In The World? Steve Weiss Believes So

Moderna Inc (NASDAQ: MRNA) is on the move Thursday following strong quarterly financial results. Short Hills Capital's Steve Weiss decided to pick up additional shares of the commercial-stage biotech company after the report.

Benzinga

Moderna Rallies After Earnings Print: Could A Technical Reversal Be In Sight?

Moderna Inc. (NASDAQ: MRNA) shares are trading after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Benzinga

What's Going On With Moderna Shares Today?

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Benzinga

Moderna Beats On Q4 Earnings, Announces $3B Buyback; Expects ~$19B In FY22 COVID-19 Vax Sales

Moderna Inc (NASDAQ:MRNA) reports a Q4 EPS of $11.29, a turnaround from an EPS loss of $(0.69) a year ago, beating the consensus estimate of $9.90. The Company clocked Q4 revenues of $7.21 billion compared to just $571 million a year ago, beating the consensus of $6.79 billion. Product sales were $6.9…

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.